Medicilon appointed Dr. Rui Zhang as Senior VP of Pharmaceutical Research

Recently, Shanghai Medicilon Inc. (hereinafter referred to as "Medicilon") appointed Dr. Rui Zhang as Senior Vice President of Pharmaceutical Research.

After this appointment, Dr. Zhang will further promote Medicilon to enter the CDMO field, help Medicilon to establish a large-scale production base in line with GMP standards through strategic cooperation, self-construction or merger and acquisition, further improve the crystal research service platform, strengthen the construction of technical platform in the field of small nucleic acid drugs and polypeptide drug preparations, and help Medicilon achieve "CRO+CDMO" two-wheel drive. At the same time, Dr. Zhang will also further promote the business development of Medicilon and help Medicilon to research and develop new drugs.

Dr. Rui Zhang.jpg

Dr. Rui Zhang, Ph.D., University of Victoria, Postdoc at the School of Pharmacy, University of Manitoba, has been deeply involved in the field of drug research and development for 15 years. He has led the development of 6 small molecule PCC drugs and successfully pushed several small molecule new drug projects to the clinical stage. He has completed a number of NDA, IND, PLGA excipient applications, has been responsible for a number of new drug CMC work, and developed a number of international and domestic leading process projects. Dr. Rui Zhang has extensive experience in the whole-process development of new drugs, improved new drugs (including high-end complex preparations) and generic drugs, and will help Medicilon to empower all aspects of new drug research and development, including product development, quality research, change control, production and declaration. Dr. Zhang was selected as a talent in Sichuan's "Tianfu Emei Plan", Shandong's "Taishan Industry Leading Talent" and Yantai's "Double Hundred Plan".

Prior to joining Medicilon, Dr. Rui Zhang served as Vice President of Research and Development and head of the Chemical Department at Shandong Luye Pharma Group, where he was responsible for drug discovery, drug development, CMC and the group's chemical R&D department. Prior to this, Dr. Zhang served as Jinan Kanghe Medical Science & Technology Co., LTD., AstaTech-Chengdu, CanAm Bioressearch Inc., and CombiPhos Catalysts Inc.Senior executive, has accumulated rich experience in drug research and development practice and team management.

The Medicilon Process Department is deeply involved in the entire industrial chain system of the R&D, procurement and production, from preclinical small-scale synthesis route optimization, process development and scale-up, process validation, quality research to commercial production.

Pharmaceutical CDMO can provide clients with innovative R&D services including process chemistry, formulation and industrial production. Pharmaceutical CDMO fully integrates and deeply connects all phases of drug R&D, including the preclinical study, the clinical trials and the commercialization.

In Vitro Enzyme Activity Assay

Kinases play extensive and important roles in signal transduction and co-ordination of complex functions. Currently, about 300 kinase inhibitors have been approved for marketing, among which receptor tyrosine kinase (RTK) inhibitors are the main ones. Medicilon provides high-quality kinase profile screening and has one-stop kinase research services from assay development, high-throughput screening to selectivity analysis. In addition, Medicilon provides many other enzyme activity screens. Wide Variety Provides 200+ in vitro enzymatic detection methods; 100+ kinases, including CTK, RTK, AGC, CMGC and other kinase families as well as important common mutations Project Flexibility Various types of plates for screening, such as 96 and 384; Multiple flexible kinase profiles, including TK kinase family, CDK kinase family, etc., to meet different customer customization needs. Various Methods Fluorescence detection; Chemiluminescence detection; Absorbance detection LanthaScr...

阅读全文

Fluorescence Probes Synthesis

Medicilon's fluorescent probes and labeling platforms can provide fluorescent probe design and synthesis services for scientific institutions, drug R&D companies, and other customers. Design and synthesis steps Fluorescent probes are tools used to detect, measure and analyze biomolecules, cells and tissues. They achieve these purposes by emitting and receiving fluorescent signals. Medicilon can complete the design and synthesis of fluorescent probes for biomolecules. Selection of target molecules and determination of target. Selection of fluorescent dyes. Design of molecular structure. Synthesize probe molecules. Testing the properties of probe molecules. Custom synthesis Medicilon's fluorescent probes and labeling platforms can provide fluorescent probe design and synthesis services for scientific institutions, drug R&D companies, and other customers. After years of development, Medicilon's fluorescent probes and labeling platforms have accumulated rich experience...

阅读全文

Custom Synthesis

Medicilon has synthesized over 10,000 individual compounds from gram to kilogram quantities, and many compounds are synthesized with more than ten synthetic steps. The overall synthesis success rate is over 95%. High quality products from mg to kg scale Reagents, intermediates, building blocks, and scaffolds Preparation of API or reference standards Development of synthetic routes for impurities and metabolites On-site analytical support Product delivered with COA Medicilon offers integrated drug discovery services -- Chemistry, Biology & Preclinical Services

阅读全文

Shanghai Medicilon Inc.

搜索此博客